Moderna, Inc. (NASDAQ: MRNA) announced that the U.S. Food and Drug Administration has approved updated 2026-2027 formulations of two COVID-19 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE